Go Pro
→ The comeback story of the century (ticker inside) (From InvestorPlace) (Ad)tc pixel
NYSE:BHVN

Biohaven Q4 2024 Earnings Report

Biohaven logo
$14.33 -0.32 (-2.20%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$14.23 -0.10 (-0.68%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Biohaven EPS Results

Actual EPS
-$1.85
Consensus EPS
-$1.56
Beat/Miss
Missed by -$0.29
One Year Ago EPS
N/A

Biohaven Revenue Results

Actual Revenue
N/A
Expected Revenue
$100.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biohaven Announcement Details

Quarter
Q4 2024
Date
3/3/2025
Time
Before Market Opens
Conference Call Date
Sunday, March 2, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Biohaven's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Biohaven's Q4 2024 Press ReleasePress Release
(8-K)

Biohaven Earnings Headlines

Biohaven Ltd. (NYSE:BHVN) Receives Average Recommendation of "Moderate Buy" from Analysts
July 25 at 2:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30919848
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
July 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biohaven-to-present-new-clinical-data-at-esmo-congress-on-bhv-1530-a-novel-fgfr3-directed-adc-with-a-proprietary-topoisomerase-i-topoix-payload-302829238.html
America Is Following in Greece's Footsteps
Italy in the 90s. Argentina in 2001. Greece in 2009. America was always safe… But now the IMF is projecting that by 2031, US debt will climb to 140% of GDP. That's higher than Greece's debt was when their entire economy collapsed. When Greece broke, the EU swooped in with $300 billion in emergency bailouts. Greece was fine. But when America crosses that line? There's no one bigger to save us. We ARE the emergency bailout for the rest of the world. You can't fix $38 trillion in debt. You can't stop Congress from spending. But you CAN control how much of your wealth stays exposed to the fallout.tc pixel
July 26 at 1:00 AM  |  Decentralized Masters (Ad)
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy?
July 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biohaven-bhvn-r-d-shake-061150596.html
Biohaven Revamps Scientific Leadership to Drive Discovery
July 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/biohaven-revamps-scientific-leadership-to-drive-discovery?utm_source=marketbeat.com&utm_medium=referral
Biohaven Announces Scientific Leadership Transitions
July 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biohaven-announces-scientific-leadership-transitions-302822263.html
See More Biohaven Headlines

About Biohaven

Biohaven (NYSE:BHVN) (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine. Its lead product, rimegepant—commercially marketed under the name NURTEC® ODT—has been approved for both acute migraine relief and migraine prevention in adults. Biohaven’s pipeline also includes atogepant, a once-daily oral CGRP receptor antagonist in late-stage development for migraine prevention, as well as earlier-stage candidates targeting N-methyl-D-aspartate (NMDA) receptors for chronic pain and other neurological disorders.

In addition to its internal programs, Biohaven has established global licensing agreements and co-development partnerships to expand the reach of its migraine therapies in key markets such as Europe, Canada and Asia. The company leverages a hybrid model of in-house development and external collaborations to accelerate clinical progress and broaden patient access.

Under the leadership of Founder and Chief Executive Officer Dr. Vlad Coric, Biohaven has built a multidisciplinary management team with deep experience in neuroscience drug development and commercial operations. Together, they aim to advance the company’s portfolio through late-stage clinical trials and regulatory submissions, with the goal of delivering novel treatments that improve patient outcomes in neurological and central nervous system disorders.

View Biohaven Profile
Earnings Tools